Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib + Azacitidine in Untreated MDS, AML, or CMML
NCT02367456Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2015
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of glasdegib in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) (2 cohorts), sponsored by Pfizer. Primary endpoints: Treatment-Emergent Adverse Events at 15 months, Serious Adverse Events at 15 months and 2 more. Started Apr 2015; status: completed.
02
Drugs
glasdegib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02367456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367456.